Literature DB >> 22647365

The therapeutic potential of microRNAs in cancer.

Stine B Thorsen1, Susanna Obad, Niels F Jensen, Jan Stenvang, Sakari Kauppinen.   

Abstract

MicroRNAs (miRNAs) have been uncovered as important posttranscriptional regulators of nearly every biological process in the cell. Furthermore, mounting evidence implies that miRNAs play key roles in the pathogenesis of cancer and that many miRNAs can function either as oncogenes or tumor suppressors. Thus, miRNAs have rapidly emerged as promising targets for the development of novel anticancer therapeutics. The development of miRNA-based cancer therapeutics relies on restoring the activity of tumor suppressor miRNAs using double-stranded miRNA mimics or inhibition of oncogenic miRNAs using single-stranded antisense oligonucleotides, termed antimiRs. In the present review, we focus on recent advancements in the discovery and development of miRNA-based cancer therapeutics using these 2 approaches. In addition, we summarize selected studies, in which modulation of miRNA activity in preclinical cancer models in vivo has demonstrated promising therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22647365     DOI: 10.1097/PPO.0b013e318258b5d6

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  54 in total

Review 1.  Strategies for combining immunotherapy with radiation for anticancer therapy.

Authors:  Steven N Seyedin; Jonathan E Schoenhals; Dean A Lee; Maria A Cortez; Xiaohong Wang; Sharareh Niknam; Chad Tang; David S Hong; Aung Naing; Padmanee Sharma; James P Allison; Joe Y Chang; Daniel R Gomez; John V Heymach; Ritsuko U Komaki; Laurence J Cooper; James W Welsh
Journal:  Immunotherapy       Date:  2015-08-27       Impact factor: 4.196

Review 2.  MicroRNAs and other non-coding RNAs as targets for anticancer drug development.

Authors:  Hui Ling; Muller Fabbri; George A Calin
Journal:  Nat Rev Drug Discov       Date:  2013-11       Impact factor: 84.694

3.  Hsa-miR-376c-3p targets Cyclin D1 and induces G1-cell cycle arrest in neuroblastoma cells.

Authors:  Swapnil Parashram Bhavsar; Cecilie Løkke; Trond Flægstad; Christer Einvik
Journal:  Oncol Lett       Date:  2018-09-11       Impact factor: 2.967

4.  Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1.

Authors:  Hailing Liu; Yan Wang; Xin Li; Yan-jun Zhang; Jie Li; Yi-qiong Zheng; Mei Liu; Xin Song; Xi-ru Li
Journal:  Tumour Biol       Date:  2013-02-22

5.  MAPK and JAK/STAT pathways targeted by miR-23a and miR-23b in prostate cancer: computational and in vitro approaches.

Authors:  Seyed Hamid Aghaee-Bakhtiari; Ehsan Arefian; Mahmood Naderi; Farshid Noorbakhsh; Vahideh Nodouzi; Mojgan Asgari; Pezhman Fard-Esfahani; Reza Mahdian; Masoud Soleimani
Journal:  Tumour Biol       Date:  2015-01-22

6.  miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation.

Authors:  Vijay Kumar Eedunuri; Kimal Rajapakshe; Warren Fiskus; Chuandong Geng; Sue Anne Chew; Christopher Foley; Shrijal S Shah; John Shou; Junaith S Mohamed; Cristian Coarfa; Bert W O'Malley; Nicholas Mitsiades
Journal:  Mol Endocrinol       Date:  2015-06-12

7.  Effects of ARHI on breast cancer cell biological behavior regulated by microRNA-221.

Authors:  Ying Li; Mei Liu; Yanjun Zhang; Chun Han; Junhao You; Junlan Yang; Cheng Cao; Shunchang Jiao
Journal:  Tumour Biol       Date:  2013-06-26

8.  Expression of MMP9, SERPINE1 and miR-134 as prognostic factors in esophageal cancer.

Authors:  Anna Agnieszka Klimczak-Bitner; Radzisław Kordek; Jan Bitner; Jacek Musiał; Janusz Szemraj
Journal:  Oncol Lett       Date:  2016-09-29       Impact factor: 2.967

Review 9.  miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma.

Authors:  Paige E Bennett; Lynne Bemis; David A Norris; Yiqun G Shellman
Journal:  Physiol Genomics       Date:  2013-09-17       Impact factor: 3.107

10.  A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer.

Authors:  Stina Mui Singel; Crystal Cornelius; Kimberly Batten; Gail Fasciani; Woodring E Wright; Lawrence Lum; Jerry W Shay
Journal:  Clin Cancer Res       Date:  2013-03-11       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.